Literature DB >> 22968102

Anti-TNF treatment blocks the induction of T cell-dependent humoral responses.

Gabriela Franco Salinas1, Leen De Rycke, Barbara Barendregt, Jacqueline E Paramarta, Hulda Hreggvidsdottir, Tineke Cantaert, Mirjam van der Burg, Paul P Tak, Dominique Baeten.   

Abstract

OBJECTIVE: Experimental and human data suggest that tumour necrosis factor (TNF) blockade may affect B cell responses, in particular the induction of T cell-dependent (TD) humoral immunity. This study aimed to assess this hypothesis directly in patients with arthritis by analysing longitudinally the effect of TNF blockade on B cell activation and the maturation of humoral responses against TD and T cell-independent vaccines.
MATERIALS AND METHODS: Peripheral blood samples were obtained from 56 spondyloarthritis patients before and after treatment with either non-steroidal anti-inflammatory drug (NSAID) alone or TNF blockers and analysed for B cell activation, plasma cell differentiation, germinal centre versus extra-follicular B cell maturation, and somatic hypermutation. Vaccine responses to hepatitis B and Streptococcus pneumoniae were measured by ELISA.
RESULTS: TNF blockade augmented B cell activation as reflected by the expression of early activation markers, CD40, and costimulatory molecules, without affecting differentiation towards plasmablasts. This was associated with a specific increase of the unswitched fraction of circulating memory B cells and a decreased level of somatic hypermutation in anti-TNF treated patients, indicating an impairment of the germinal centre-dependent B cell maturation. In agreement with these findings, TNF blockade profoundly suppressed the response to the TD vaccination against hepatitis B, whereas the T cell-independent response against pneumococcal polysaccharides was only modestly affected.
CONCLUSIONS: These data indicate that TNF blockade severely impedes the induction of primary TD humoral responses, probably by interfering with the germinal centre reaction.

Entities:  

Keywords:  Anti-TNF; Autoantibodies; B cells; T Cells; Vaccination

Mesh:

Substances:

Year:  2012        PMID: 22968102     DOI: 10.1136/annrheumdis-2011-201270

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  34 in total

Review 1.  A literature review on the patients with autoimmune diseases following vaccination against infections.

Authors:  Yan Liang; Fan-Ya Meng; Hai-Feng Pan; Dong-Qing Ye
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Combined Blockade of TNF-α and IL-17A Alleviates Progression of Collagen-Induced Arthritis without Causing Serious Infections in Mice.

Authors:  Fang Shen; Akash H Verma; Amy Volk; Brian Jones; Bianca M Coleman; Matthew J Loza; Ravi Malaviya; Beverley Moore; Daniel Weinstock; M Merle Elloso; Sarah L Gaffen; Tatiana Ort
Journal:  J Immunol       Date:  2019-02-11       Impact factor: 5.422

Review 3.  Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs.

Authors:  Francesca De Nard; Monica Todoerti; Vittorio Grosso; Sara Monti; Silvia Breda; Silvia Rossi; Carlomaurizio Montecucco; Roberto Caporali
Journal:  World J Hepatol       Date:  2015-03-27

4.  Correlations of TNF-α gene promoter polymorphisms with the risk of thymoma-associated myasthenia gravis in a northern Chinese Han population.

Authors:  H-W Yang; P Lei; Y-C Xie; Z-L Han; D Li; S-H Wang; Z-L Sun
Journal:  Cancer Gene Ther       Date:  2017-04-21       Impact factor: 5.987

5.  Therapy: Response to T-cell-dependent vaccine thwarted by TNF blockade.

Authors:  Emma Leah
Journal:  Nat Rev Rheumatol       Date:  2012-09-25       Impact factor: 20.543

6.  Plasma cell and serum antibody responses to influenza vaccine in preterm and full-term infants.

Authors:  Carl T D'Angio; Claire P Wyman; Ravi S Misra; Jessica L Halliley; Hongyue Wang; Julianne E Hunn; Caitlin M Fallone; F Eun-Hyung Lee
Journal:  Vaccine       Date:  2017-08-12       Impact factor: 3.641

7.  [Guidelines for vaccination of immunocompromised individuals].

Authors:  Ursula Wiedermann; Harald H Sitte; Heinz Burgmann; Alexander Eser; Petra Falb; Heidemarie Holzmann; Maria Kitchen; Marcus Köller; Herwig Kollaritsch; Michael Kundi; Hans Lassmann; Ingomar Mutz; Winfried F Pickl; Elisabeth Riedl; Maria Sibilia; Florian Thalhammer; Barbara Tucek; Werner Zenz; Karl Zwiauer
Journal:  Wien Klin Wochenschr       Date:  2016-07-25       Impact factor: 1.704

Review 8.  Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease.

Authors:  Alicia C Marín; Javier P Gisbert; María Chaparro
Journal:  World J Gastroenterol       Date:  2015-10-28       Impact factor: 5.742

9.  Vaccine-induced ICOS+CD38+ circulating Tfh are sensitive biosensors of age-related changes in inflammatory pathways.

Authors:  Ramin Sedaghat Herati; Luisa Victoria Silva; Laura A Vella; Alexander Muselman; Cecile Alanio; Bertram Bengsch; Raj K Kurupati; Senthil Kannan; Sasikanth Manne; Andrew V Kossenkov; David H Canaday; Susan A Doyle; Hildegund C J Ertl; Kenneth E Schmader; E John Wherry
Journal:  Cell Rep Med       Date:  2021-05-07

10.  Effects of infliximab on lung and circulating natural killer cells, CD56+ T cells and B cells in sarcoidosis.

Authors:  Susanna Kullberg; Natalia V Rivera; Johan Grunewald; Anders Eklund
Journal:  BMJ Open Respir Res       Date:  2021-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.